Literature DB >> 2239982

Interleukin-1: biology, pathophysiology, and clinical prospects.

L C Platanias1, N J Vogelzang.   

Abstract

Interleukin-1 (IL-1) is a cytokine with multiple biologic activities. Since its first description in 1972, significant work has been done, leading to an understanding of the biology of IL-1, which plays a central role in many important functions of the immune system. The biologic activities of IL-1 make it an attractive factor for use in clinical oncology, both as an antitumor agent and for the hematologic recovery of cancer patients receiving other forms of therapy. In this review the biologic effects of IL-1 are summarized. The possible involvement of IL-1 in the pathogenesis of some diseases is reviewed. Future prospects for the use of IL-1 in the treatment of malignancies are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2239982     DOI: 10.1016/0002-9343(90)90181-c

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  19 in total

Review 1.  Clinical toxicity of cytokines used as haemopoietic growth factors.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

2.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.

Authors:  J Yrjänheikki; R Keinänen; M Pellikka; T Hökfelt; J Koistinaho
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Differential regulation of IL-8 by IL-1beta and TNFalpha in hyaline membrane disease.

Authors:  K Y Kwong; C A Jones; R Cayabyab; C Lecart; C L Stotts; I Randhawa; R Ramanathan; N Khuu; P Minoo; R A deLemos
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

4.  Role of cytokines and their inhibitors in acute pancreatitis.

Authors:  A Kingsnorth
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

5.  Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model.

Authors:  C Liu; B F Kimler; R G Evans; R A Morantz
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

6.  Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies.

Authors:  E Toussirot; P Lafforgue; J Boucraut; P Despieds; A Schiano; D Bernard; P C Acquaviva
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

7.  Histiocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state.

Authors:  S Ohga; A Ooshima; J Fukushige; K Ueda
Journal:  Eur J Pediatr       Date:  1995-07       Impact factor: 3.183

8.  A morphological analysis of the short-term effects of benzene on the development of the hematological cells in the bone marrow of mice and the effects of interleukin-1 alpha on the process.

Authors:  R Niculescu; G F Kalf
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

9.  Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients.

Authors:  Sebastian Niedźwiecki; Tomasz Stepień; Krzysztof Kuzdak; Henryk Stepień; Roman Krupiński; Daniel Seehofer; Nada Rayes; Frank Ulrich
Journal:  Langenbecks Arch Surg       Date:  2007-12-07       Impact factor: 3.445

10.  Infusions of interleukin-1 alpha after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity.

Authors:  E Katsanis; D J Weisdorf; Z Xu; B B Dancisak; M L Halet; B R Blazar
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.